Abstract
PUVA (psoralen plus ultraviolet A) phototherapy is the use of a photosensitizing medication (8-methoxypsoralen/methoxsalen/Oxsoralen Ultra) in combination with ultraviolet A (UVA) phototherapy. PUVA is used to treat moderate to severe psoriasis, generalized psoriasis, or psoriasis that is unresponsive to topical treatments. In systemic PUVA, patients take oral methoxsalen and are subsequently exposed to UVA. In topical and bath PUVA, patients expose their skin to psoralens by soaking in water containing methoxsalen or applying a topical formulation of methoxsalen, followed by exposure to UVA. Patients are treated three times per week for at least 12 week and potential ongoing maintenance treatment is required. PUVA penetrates deeper into the skin and may be more effective than UVB. Potential side effects of PUVA include burning, itching, and pigmentation of the skin, as well as nausea with systemic PUVA. There is an increased risk of skin cancer in Caucasian patients who undergo more than 250 treatments of PUVA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Morison WL, Richard EG. Systemic and topical PUVA. In: Koo JYM, Levin EC, Leon A, Wu JJ, Gottlieb AB, editors. Moderate to severe psoriasis. Baton Rouge: CRC Press; 2014. p. 99–138.
Kerr HA, Lim HW. Photobiology and phototherapeutics. Adv Dermatol. 2003;19:11–36.
Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;291(23):1207–11.
Tanew A, Radakovic-Fijan S, Schempter M, et al. Narrowband UV-B phototherapy vs. photochemotherapy in the treatment of chronic plaque-type psoriasis. Arch Dermatol. 1999;135:519–24.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114–35.
Farahnik B, Nakamura M, Singh R, et al. The patient’s guide to psoriasis treatment: part 2. PUVA phototherapy. Dermatol Ther. 2016;6(3):315–24.
Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 1977;68(6):328–35.
Morison WL, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol. 1997;36(2 Pt 1):183–5.
Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231–7.
Wang E, Sasaki J, Nakamura M, Koo J. Cutaneous carcinogenic risk of phototherapy: an updated comprehensive review. J Psoriasis and Psoriatic Arth winter. 2015;1(1):44–51.
Stern RS, Bagheri S, Nichols K. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol. 2002;47(1):33–9.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Koo, J., Nakamura, M. (2017). PUVA for the Treatment of Moderate to Severe Psoriasis. In: Clinical Cases in Phototherapy. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-51599-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-51599-1_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-51598-4
Online ISBN: 978-3-319-51599-1
eBook Packages: MedicineMedicine (R0)